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Duringembryonicdevelopmentpluripotencyisprogressivelylostirreversiblybycelldivision,diﬀerentiation,migration,andorgan
formation. Terminally diﬀerentiated cells do not generate other kinds of cells. Pluripotent stem cells are a great source of varying
celltypesthatareusedfortissueregenerationorrepairofdamagedtissue.Thepluripotentstemcellscanbederivedfrominnercell
mass of blastocyst but its application is limited due to ethical concerns. The recent discovery of iPS with deﬁned reprogramming
factors has initiated a ﬂurry of works on stem cell in various laboratories. The pluripotent cells can be derived from various
diﬀerentiated adult cells as well as from adult stem cells by nuclear reprogramming, somatic cell nuclear transfer and so forth. In
this review article, diﬀerent aspects of nuclear reprogramming are discussed.
1.Introduction
Adult human beings cannot regenerate organs as the
regeneration has silenced during evolution to protect from
tumorigenesis. However, in human, part of the liver can
regenerate. In lower animals, regeneration of organs or part
of organs are very common. Song birds’ brain tissue that
controls the singing of birds dies after every breeding season
and that lost neuron is again are replaced at the advent of
next breeding season [1]. Reptiles like lizards lose their tail
to deceive predators and the lost tail regenerates. Terminal
diﬀerentiated cells like ﬁbroblasts are thought to be unable
to convert to other cell types. However, cloning experiments
inamphibiansandlaterinmammalsprovedthatindeedthey
have the potential to reprogram and generate other cell types
[2, 3].
Human adult neurons, heart tissues never thought to
regenerate but in the late 90’s it was found that in occasional
cases human adult neurons divide [4].
It is now established that terminal diﬀerentiation of cells
is a reversible process that has generated a lot of interest in
reversion of cell diﬀerentiation and reprogramming to iPS.
Stem cells can divide unlimitedly and can give rise to its own
and diﬀerent kinds of adult cells. It holds the promise for
the treatment of several neurological and other debilitating
diseases like Parkinson, Alzheimers, ischemic heart failure,
diabetes mellitus, Huntington disease, and sickle cell anemia
[5].
2.Sourcesof PluripotentCells
Several methods of pluripotent cell derivation exist. (a)
Embryonic stem (ES) cells can be harvested directly from
the inner cell mass (ICM) of preimplantation blastocyst.
(b) Somatic cell nuclear transfer (SCNT) is a therapeutic
technique where adult somatic nuclei are microinjected
into enucleated eggs. The egg, now containing the nucleus
of a somatic cell, is stimulated with a shock and the
somatic cell nucleus is reprogrammed by the host egg cell
and forms a blastocyst. (c) Cellular hybridization where
pluripotent hybrid cells are formed via somatic cell fusion
with an ES cell. (d) Induced pluripotent stem (iPS) cells are
developed from-patient-speciﬁc somatic cell reprogrammed
to an ES cell-like state. For practical purpose, hES cells
have faced diﬃculties because of ethical issues, potential
immuno-incompatibility, and an increase of MHC molecule2 Stem Cells International
Table 1: Nuclear reprogramming: various cell types that can be reprogrammed are shown in Table 1. During reprogramming several cell




Keratinocytes, t-cells, ﬁbroblasts, Adipose-derived stem cells (ADSCs), mesenchymal stem cells (MSCs), dental pulp




(a) Embryonic development—upregulated (Oct4, Sox2, Nanog, Lin-28, NR5A2, TBX3, STAT3 and ZIC3).
Downregulation of diﬀerentiation speciﬁc genes (PAX6, ATBF1 and SUZ12).
(b) Proliferation—upregulated (Cyclin D1, c-Myc, KLF4, Rem2).
Downregulated (p53, p21, p16INK4A).
(c) Epigenetic—downregulated (DNMT1, HDAC, Histone demethylase).
(d) Signalling pathway—downregulated (TGFβ, Wnt/β catenin, PI3/AKT).
(e) Chromatin—opened (by SWI/SNF).
(f) Miscelleneous—to express (Vitamin C, hypoxia, TERT, E-cadherin).
expression during diﬀerentiation [6]. SCNT for humans are
diﬃcult to achieve and mired with ethical issues related
to egg destruction. Similarly, the utilization of ES cells has
been diﬃcult due to ethical reasons. As an alternative to ES,
the establishment of iPS cells has raised more interesting
potential as they are created from adult cells [7]. In his
seminal work on iPS, Yamanaka et al. used 4 reprogramming
factors (they are also transcription factors) such as Oct3/4,
Sox2, Nanog, and c-Myc to reprogram mouse somatic
cells. Later, reprogramming factors (RFs) delivery were
done by retroviral and lentiviral vectors and other nonviral
delivery systems (Table 1). The minicircle (MC) delivery
system is designed to deliver TFs episomally to avoid the
unintended consequences of viral use in the clinical setting
[8].Recently,however,mRNA with4 reprogramming factors
added directly to the cell demonstrated a high eﬃciency
of reprogramming of adult skin cells [9]. Reprogramming
eﬃciency has also improved with the use of various chemical
compounds and growth factors (such as Wnt and TGF-β
signaling pathways) in addition to 4 reprogramming factors
(Figure 1).
3.ESandiPSCells
ES and iPS cells have the ability to produce almost any
types of adult cells. However, use of ES cells for clinical
purpose is controversial. Additionally, cells derived from
ES cells can be rejected by the host immune system as
they are autogenously derived. To overcome the ethical
and immune rejection issues, iPS cells are developed from
adult diﬀerentiated cells by reprogramming factors. This iPS,
which is morphologically and characteristically close to ES,
can be diﬀerentiated to various types of tissues and replenish
host tissue loss in neurodegenerative and other diseases.
Direct reprogramming of cells by iPS is more convenient and
reliable than generation of pluripotent cells from ICM of
blastocyst [10]. However, diﬀerent studies have shown that
iPS cells are not as superior as ES cells.
Before starting any reprogramming, we need to under-
stand genetic and epigenetic changes at the molecular level
that causes reprogramming from a diﬀerentiated cell to a
pluripotent one. There is a gulf between lab bench success on
iPS and clinical application of this technology as still charac-
terization is taking place. For the safety concerns need to be
addressed before any clinical consideration. The bottlenecks
of iPS are inadequate cell number, immune rejection, and
tumor(teratoma)formation.Allthepluripotentcells(hESC,
iPS,andNTSC)arepotentiallytumorigenic.Moreresearchis
needed to overcome this problem [11].
4. Cell Types for Reprogramming
Before starting any reprogramming, information about the
plasticity of the starting cell is helpful as cellular reprogram-
ming is an interplay between plasticity and environmental
factors like epigenetic modiﬁcations. Both adult stem cells
and terminally diﬀerentiated cells can be reprogrammed
but eﬃciency, time period, and extent of reprogramming
varies among the starting cells. The derivation of functional
neurons, cardiomyocytes, pancreatic islet cells, hepatocytes,
and retinal cells prove that it is possible to derive cells
from many sources of tissues by reprogramming, thus
facilitating the various treatments. The starting cells should
not be necessarily from the organ that will require repair.
As an example, regeneration of insulin-producing cells can
be done from primary source (in this case pancreatic β
cells), insulin-producing cells can be also derived from other
alternative sources like ES, adult stem cell, mesenchymal and
hematopoietic stem cells. This was also achieved by various
means like nuclear reprogramming and transdiﬀerentiation.
Bone marrow tissues are a source of adult mesenchymal stem
cells but are collected by more invasive and painful surgery.
Adipose-derived stem cell (ADSC) is the most abundant and
can be easily isolated from the patient by local anesthesia.
Interestingly fat tissues contain about 100-fold adult stem
cells more than bone marrow making it an attractive source
for adult stem cells. Human ADSCs are a heterogeneous
group of multipotent progenitor cells and it has certain
advantages; they can be collected autogenously in high
numbers (100mL of human adipose tissue yields about 1 ×
106 cells) with minimal morbidity [12]. Additionally, ADSCs
e x p r e s s3 - 4t i m e se n d o g e n o u sK l f 4c o m p a r e dt oh u m a n
ES cells and 1.3 times higher expression of c-Myc both

















Figure 1: A simpliﬁed version of reprogramming of adult cells to pluripotent cells by 4 factors. (a) Any adult source of cells like epithelial,
muscle, ﬁbroblast, and adipose cells is isolated and cultured in appropriate medium. Then cells are transfected, nucleofected, or transduced
by 4 reprogramming factors. These factors may be Oct3/4, Sox2, Nanog, and Klf4/c-Myc. The reprogramming paths are not well understood
yet, requiring expression of several genes as well as epigenetic modiﬁcation of the genome. (b) Reprogramming factors (transcription factor
genes)canbedeliveredbyvariousmethods.Incaseofviralgenedelivery,genesareintegratedwiththehostchromosomerandomly.Methods
of gene deliveries like plasmids, mRNAs, proteins, genes are expressed transiently and diminished the expression with the concomitant
increase in expression of pluripotent markers.
iPS and subsequent neuronal diﬀerentiation is an attractive
alternativetohES.ADSCscanbeinducedtodiﬀerentiateinto
osteogenic [13], chondrogenic [14], adipogenic [15], hepatic
[15], cardiogenic [16], neurogenic [17], islet-like insulin
secreting cells [18], and hematogenic (mouse) lineages [19].
5. The Reprogramming Vectors
5.1. Reprogramming by Retroviral Vectors. The reprogram-
ming with gene delivery system that remains as episome
(likeadenovirus,mRNA,andminicircle)hasgreatadvantage
over the integration of genes into the host chromosome
(hantavirus, retrovirus). The reprogramming factors are
expressed transiently and then degraded or diminished. This
primes and drives the host cell to a choreography of down-
stream reactions (pathways are not yet well understood) that
ultimately convert the cell to pluripotency. For DNA-based
(viral vector) reprogramming, 4 proteins trigger reprogram-
ming but DNA remains altered due to viral integration into
the chromosome. Nevertheless, the eﬃciency of retroviral
reprogramming is at very low frequency (less than 0.1%). In
the original reprogramming method a retrovirus (MMLV)
was used; the RNA virus carried the transgene and reverse-
transcribedinsidethehostcell.ThisDNAwasintegratedinto
thehostchromosomeandwasaconstantsourceoftransgene
protein. The retroviral promoter was inactivated probably
byhistonemodiﬁcation(methylation)[20].Reprogramming
of adult cells by viral delivery of 4 reprogramming factors
(Oct4, Sox2, Nanog, and c-Myc) have been used successfully
for iPS generation. Takahashi et al. ﬁrst developed mouse iPS
and one year later established human iPS [7, 21]. These iPS
cells are supposed to be equivalent or comparable to ES cells
in morphology, gene expression, and epigenetic status and
can give rise to 3-germ layers. There are some disadvantages
of retroviral vectors. It integrates randomly in host chro-
mosome making leaky expression and transforms the cell
into tumor. Besides, the random integration also makes cells
heterogeneous and iPS cells should be screened for various
clones (eﬃcacies and safety). Using c-myc as an agent of
reprogramming factors makes cell more tumorigenic as the
role of myc has been well documented in connection with
tumor. Myc is an immediate early gene and reactivation
of c-Myc gave rise to transgene-derived tumor formation
in chimeric mice [22]. Chimeric mice produced with c-
myc-free iPS did not develop any tumor until 6-month
observation period compared to control mice. Besides c-
Myc, various tumors also express OCT3/4, SOX2, and KLF4
theother3reprogrammingfactors.Overexpressionofthese3
factor-derived iPS causes tumor formation. Hopefully, there
are some reﬁnements to the above procedures. Some labs
have minimized the number of integration into the host
genome by putting all reprogramming factors in one vector.
This is technically/practically accomplished by putting IRES
sequence between reprogramming genes or a self -cleavage
2A peptide sequence. This way iPS cells are produced with
only single insertion in the genome [23].
5.2. Reprogramming by Nonviral Vectors. Until now, there
have been several nonviral vectors designed for TFs delivery.
A partial list of them is shown in Table 2. Minicircle (MC)
vectors have been developed by Dr. Joseph Wu’s team at4 Stem Cells International
Table 2: Nuclear reprogramming factor delivery. List of reprogramming factors delivery by various methods shown in Table 2.
Mode of delivery Vectors
Viral delivery MMLV retrovirus, lentivirus, adenovirus, hantavirus, transposon, retrotransposon.
Episomal delivery PiggyBack, plasmid, minicircle, synthetic mRNA, IVT mRNA, protein, cell fusion (ES + adult),
cell fusion (tumor + adult), protein delivery by gag protein,
Small molecule (chemical) ALK5 inhibitor, GSK3 inhibitor, and MEK inhibitor.
Stanford University [8]. Minicircles (MC) are circular non-
viral DNA elements that are generated by an intramolecular
(cis-) recombination from a parental plasmid (PP) pLGNSO
(Lin28, GFP, Nanog, Sox2, and Oct3/4) mediated by φC31
integrase.Thusdeliveringonlytheminicirclestocellslength-
ens the expression of the transgene over traditional transient
transfection of plasmids. For dividing cells, expression of
the minicircles lasts up to 14 days. For nondividing cells,
expressions of the minicircles drop slightly after the 1st
week, but can continue the expression of transgenes for
months. The beauty of minicircle is that MC possesses
higher ectopic expression and less inactivation by cellular
machineries. The plasmid contains a single cassette of 4
reprogrammingfactorsandGFPcodingsequencesarelinked
by “2A” peptide sequences [24]. The minicircle when used
to transfect the adult cell, gradually over time becomes
ES type morphology without changing the global gene
expression. Inside the cell, the MC is not integrated in the
genome, but instead it is transcribed as a whole single long
mRNA containing all the 5 genes (4 RFs & GFP). This is
translated as a single protein where individual proteins are
processed by self-cleavage peptide 2A. In case of synthetic
RNA-based reprogramming RNA is translated into protein
in the cytoplasm and host DNA remains unaltered. So,
synthetic RNA-based reprogramming is clean, safe, and fast
and iPS cells are genetically identical to their source cells.
The reprogramming process takes a little over 2 weeks with
4% of the cells being reprogrammed. This is about 100-
fold more eﬃcient than reprogramming by gene transfer
technique[9].TheynameditRNA-inducedpluripotentstem
(RiPS) cells. However, it is diﬃcult to synthesize long mRNA
chemically and researchers have not been able to make large
mRNAs. Needless to say mRNA is prone to degradation
and needs very rigorous quality control in the lab. The
cells have a defense system against RNA virus infection.
That is an old defense mechanism present in both plants
and animals. The host cell perceives foreign RNA as a viral
invasion and degrades RNA in small fragments by RISC
machinerythatisavailableinsidethecells.Thiscell-mediated
RNAdegradationisknownasRNAinterference(RNAi)[25].
To circumvent that problem, Dr. Rossi’s team chemically
synthesized mRNA with some modiﬁed bases (nucleotides)
at intervals so it is not recognized as an outsider RNA and
protected from degradation. Yakubov et al. also conﬁrmed
reprogramming by mRNA of 4 TFs. However, they did not
use synthetic RNA instead they used mRNA which was
synthesized by in vitro transcription (IVT) from the DNAs
of4genes.Forcontinuousexpression,theytransfectedatotal
of ﬁve times and established iPS that is alkaline phosphatase
positive and expressed several pluripotent markers [26].
5.3. Model Reprogramming of Cells: hADSCs. Human ADSCs
are a heterogeneous group of multipotent progenitor cells
that can be collected autogenously in high numbers [27].
ADSCS are more abundant than bone marrow by a factor
of 100. Nucleofector (Amaxa, Germany) is used for nucle-
ofection with 4 reprogramming factors. Nucleofection is a
poorly explained method where DNA materials are directly
deliveredtothenucleus.Allcellsareusedforreprogramming
are within early passage. Transfected hADSC cells are then
seeded onto a Mitomycin C treated MEFs feeder layer or
on Matrigel-coated tissue culture dishes (ES qualiﬁed, BD
Biosciences). The feeder layer provides nutrition for the cells
that are being reprogrammed. Mitomycin C or radiation
treated cells are alive but they do not divide as the cell
cycle is arrested by DNA damage response pathway. On
days 4 and 6, hADSCs are transfected again with minicircles
using lipofectamine type transfection reagent which is less
toxic to the cells than nucleofection. Cells were switched
to human ES cell culture medium prepared using DMEM-
F12+ 10% knockout serum and 100ng/mL of bFGF (FGF-
2). Colonies with morphologies similar to human ES cell
colonies are expected to be visible in 3-4 weeks after
transfection. Gradual loss of GFP expression due to dilution
of minicircles followed by activation of endogenous Oct4
expression will be observed on successive cell proliferative
cycles. During this reprogramming, cells divide and form
round/circular compact colony of cells with a clear margin.
In mouse cell reprogramming, leukemia inhibitory factor
(LIF) is also used in the media to keep them in a pluripotent
state while avoiding any diﬀerentiation.
The pluripotency of the iPS cells is determined by
immunoﬂuorescence for ES markers like Oct4, Sox2, Nanog,
and so forth. For clinical applications, Southern blots are
done to check any genomic integration of reprogramming
genes. The isolated colonies look morphologically similar
to hES. Immunostains for pluripotent markers and alkaline
phosphatase will be positive. iPS cells typically express
SSEA4, TRA-1-60, and Nanog but not SSEA1.
5.4.SomeLessUsedReprogrammingMethods. Various Gram-
negative bacteria have type III secretion system (T3SS) that
injects virulent proteins (regulated by a variable secretion
signalsequence)intotheeukaryoticcellcytoplasm.Bichselet
al.usedPseudomonasaeruginosaexotoxinExoStotranslocate
Cre recombinase containing a Cre-NLS signal [28]. Upon
infection,bacteriadeliveredCre-NLStoundergoLoxPmedi-
ated chromosomal DNA recombination. This resulted in iPS
and establishes the use of T3SS for the delivery of TFs in
cellular reprogramming. Retroviruses assemble polymer of
Gag protein which is proteolytically cleaved before enteringStem Cells International 5
thecellthroughreceptorbinding.Thispropertyofretrovirus
was used to deliver the reprogramming proteins into the
cells. Proteins were incorporated with nuclear localization
signal (NLS) and tagged/attached to the retroviral protein.
After cell entry, proteins were cleaved by retrovirus protease
and the active TFs proteins were translocated inside the
nucleus where it reprograms the cells. This expression is
transient as proteins will be degraded after their intended
job [29]. In routine iPS generation, germ-line transmission
a n dl i v eb i r t hf r o mi P Sc e l l sa r ep r o d u c e db yt e t r a p l o i d
complementation. It has been shown that addition of Tbx3
improves the quality of iPS cells. iPS cells derived with Tbx3
and Oct 4, SOX2, KLF4 are more successful in germ cell
contribution [30].
Dermal papilloma (DP) cells are reprogrammed more
eﬃciently than skin and embryonic ﬁbroblasts. DP inher-
ently express higher levels of SOX2 and c-Myc, so these
DPs can be easily reprogrammed with only Oct4 and
KLF4 [31]. Among the 4 reprogramming factors, Oct4 is
a very important TF for iPS generation. Oct4 cannot be
replaced with other TF whereas SOX2, KLF4 and c-Myc
can be replaceable. However, Ng has shown that orphan
(ligand is not known for the receptor) nuclear receptor
Nr5a2 can be used for mouse somatic cell reprogramming
with greater eﬃciency than Oct4. Genomewide expression
analysis showed that Nr5a2 shares many target genes with
SOX2 and KLF4 indicating they work together in concert
[32]. The nuclear receptor superfamily has 48 genes. This
nuclear receptor superfamily maintain various aspects of
stem cell-like regulation of stemness, reprogramming of
terminallydiﬀerentiatedcells[33].AnOct-4promoter-based
reporter system has been developed in mouse and pig and
is a useful tool for monitoring the diﬀerentiating status of
porcine cells both in vivo and in vitro [34]. A recent work by
Sugii et al. have improved the iPS eﬃciency with or without
the feeder layer [35]. They also demonstrated that adipose
stem cells (ASC) can be grown on ASC feeder layer instead
of the MEF feeder layer. They reduced the iPS programming
1.5 and 2.5 weeks for mouse and human iPS, respectively.
Terminally diﬀerentiated mature B lymphocyte has been
reprogrammed with basic reprogramming factors plus the
addition of C/EBPalpha [36]. Generally 4 reprogramming
factors are added in equal ratio for iPS generation. However,
increasing the concentration of OCT3/4 enhances repro-
gramming eﬃciency but increasing the concentration of
SOX2, KLF4, and c-Myc reduces reprogramming eﬃciency
[37]. The time required for reprogramming also varies
among the starting cell types, source, and so forth. Mouse
ﬁbroblasts can be reprogrammed in 3 weeks whereas human
ﬁbroblasts with the same reprogramming factors require 4
weeks to reprogram. Interestingly, 4-factor reprogramming
repressedcardiacdiﬀerentiationduetoprolongedexpression
ofOCT4andFgf4.Contrarytothat,3-factorreprogramming
(excluding c-Myc) enhances the expression of precardiac
(CXCR4, Flk-1, and Mesp1/2) and cardiac-speciﬁc (Nkx2.5,
Mef2c, and Myocardin) genes. The diﬀerentiation of cells
showed continuous beating activity in a petri dish. So,
reprogramming devoid of c-Myc TF has a tendency of
preferentially generating cardiac tissues [38].
Human iPS induction was also done by adding sev-
eral other factors like TBX3, mirna-291-3p, miR-294, and
miR295. The adult newt can regenerate lens from pigmented
epithelial cells (PECs) through dediﬀerentiation. It is like
reprogramming iPS in vivo without any exogenous factors.
The authors were interested in seeing which genes are being
activated/expressed during the dediﬀerentiation procedure.
They isolated mRNAs and constructed a cDNA library.
Upon analysis, they found the expression of apoptosis
and cancer-related genes and concluded that cancer and
apoptosis-related genes expression may be a hallmark during
dediﬀerentiation in newt [39]. Vitamin C enhances the
generation of iPS in mouse and human somatic cells. It may
play an auxilliary role to reverse senescence and promotes
pre-iPS cells to complete programming of cells [40]. Lineage
reprogramming has been an important tool for studying cell
fate choice during diﬀerentiation. Several TFs that can drive
cells from one lineage to another [41]. Induced expression
of leukemic oncogene AML1-ETO in embryonic zebraﬁsh
reprogram hematopoietic progenitor cells from erythroid to
myeloid.
5.5. Small Chemical Molecules. Small chemicals molecules
that target enzymes of cell reprogramming pathways have
been identiﬁed that control the cells fate like stem cell
maintenance, reprogramming, and diﬀerentiation [42]. By
using small synthetic chemical molecules a pluripotent state
can be induced which is known as a chemically induced
pluripotent cell (CiPSs) [43]. Li et al. has suggested that
small molecules should not only be able to reprogram
cells in vitro, but they can also be delivered into the body
as conventional therapies to target a patient’s own tissue
for the treatment of degenerative diseases, injuries, and
cancer (to target cancer stem cells) [44]. Cancer cells get
resistant to chemotherapeutic drugs. It has been shown that
reprogramming of GI cancer cells by the ectopic expression
of TFs leads to reprogramming. The induced pluripotent
cancer (iPC) cells were sensitized to chemotherapeutic drugs
and also responded to diﬀerentiation-inducing treatment
in short term cell culture [45]. Reprogramming of somatic
cells is also possible by fusing ES cells with adult cells. In
case of fusion-induced reprogramming, OCT4 reactivation
starts within 1-2 days after ES cell and somatic cell fusion
[46]. Reprogramming by fusion was achieved by the fusion
of MEFs with mouse ES cells by using hemagglutinating
virus of Japan envelope (HVJ-E). Microsatellite analysis of
the derived stable cell line showed that they possess genes
from both ES and MEF. The fused cells were tetraploid
and positive for Alkaline Phosphatase (AP) and stem cell
markers (OCT3/4, NANOG, SOX2) but not ﬁbroblast cell
marker (Col1a1 and Col1a2) [47]. Fusion between intesti-
nal epithelial cells and macrophages in a cancer context
results in nuclear reprogramming [48]. The structure of
telomeric chromatin is dynamic and changes during cell
transformation to cancer. Telomere is shortened in every
cell cycle until it reaches a crisis stage where it goes to
apoptosis [49]. Telomere expression is silenced in most adult
somatic tissues except the adult stem cell compartments.6 Stem Cells International
During reprogramming telomeric chromatin is remodeled
and telomeres are elongated by telomerase [50], although
there are some heterogeneity during the reprogramming
process with respect to telomere length [51].
5.6. Reprogramming by Transdiﬀerentiation. Transdiﬀerenti-
ation is deﬁned as the conversion of one cell type to another.
Eberhard et al. used synthetic glucocorticoid dexamethasone
and reprogrammed pancreatic cells to hepatocytes [52].
Cobaleda C dediﬀerentiated adult B cells into multipotent
progenitor cells and afterward reprogrammed to alternative
lineages T cells and macrophages [53]. Mak et al. used
mammalian aﬃnity puriﬁcation and lentiviral expression
(MAPLE) to deliver several protein complexes involved in
transcription (RNA polymerase II associated factor, negative
elongation factor, positive transcription elongation factor b,
SWI/SNF complexes). They showed that TF KLF4 facilitates
chromatin remodelling with the SWI/SNF complex [54].
The generation of animals by SCNT has shown that
epigenome of diﬀerentiated cells can be reset to a pluripotent
state. The nucleus from the somatic cell is inserted into
an enucleated egg and can transform it into an embryonic
stage (pluripotent). The cytoplasm of the egg is enough to
reset the epigenome and DNA sequence remains unaltered.
Compatibility of mitochondrial DNA haplotypes between
donor cells and host oocytes improves reprogramming
eﬃciency possibly by epigenetic modiﬁcation. To increase
the SCNT viability, treatment with chemicals that causes
chromatin modiﬁcation like Trichostatin-A (TSA) decreases
expression of histone deacetylase (HDAC1 and HDAC2) and
DNA methylation (DNMT3a and DNMT3b) while increases
the expression of histone acetylation (P300 and CBP),
pluripotency (OCT4 and NANOG) genes [55]. Histone
deacetylase inhibitor valproic acid (VPA) enabled reprogram-
ming of human ﬁbroblasts with only Oct4 and SOX2 [56].
Wnt signalling results in inhibition of GSK-3 and stabilization
of cytoplasmic β-catenin. Small molecule inhibitors of GSK-
3 can mimic the activation of wnt signalling and main-
tain the pluripotency of mES [57–59]. An immune system
protein, activation-induced cytidine deaminase (AID) helps
in reprogramming by DNA methylation. Thus important
reprogramming genes Oct4 and nanog are induced. Li et
al. has been able to reprogram somatic cells without the TF
Sox2. TFs Oct4, and KLF4 alone can reprogram MEF when
cultured with glycogen synthase kinase-3 (GSK-3) inhibitor
CHIR 99021. They conclude that GSK-3 inhibitor may
replaceTFSOX2inbothmouseandhumanreprogramming.
Additionally, CHIR 99021 in combination with parnate, TFs
Oct4, and KLF4 are suﬃcient for reprogramming of human
primary keratinocytes [60].
6. In Vitro Differentiation of iPS Cells to
Differentiated Cells
Pluripotent iPS is like a hub from where diﬀerentiation to
various lineage types is possible. For generation of mature
neuron cells from iPS, cells are induced with culture media
containing diﬀerentiation factors. Expression of diﬀerenti-
ation marker is determined by the presence of α-smooth
muscle actin, α-fetoprotein, and β-III tubulin. If viability
of iPS cell is a problem, treatment of iPS cells with ROCK
inhibitor Y-27632 before harvesting to increase their viability
is possible. Recently cells can be induced to transdiﬀer-
entiation by treatment with several transcription factors
and transform cell from one lineage (ﬁbroblast) to another
(functional neuron) bypassing the conversion of pluripotent
stem cell-like stage [61].
7. Developing of Embryo, Pluripotent Stem
CellsandCancerCells
Embryo, pluripotent stem cells and cancer cells have some
similarity in behavior. They are actively dividing and pro-
liferated. Many genes which are silent (unexpressed) in the
diﬀerentiated adult tissue are reactivated during cellular
reprogramming (iPS) and cancer as well. Back in time, the
ﬁrst pluripotent cells were derived from teratocarcinoma
(a germline tumor). When (explanted) grown in tissue
culture, teratocarcinoma generated embryonic carcinoma
cells. This happens due to reprogramming of cancer cell to a
pluripotentstate[62].Therefore,itneedscarefulobservation
to limit the growth of iPS towards tumors/malignancy.
The success of iPS in clinical setting will be determined
by safety, genomic integrity, programming eﬃciency, and
so forth. The Rb-p53-p16 (INK4a) is a very important
pathway for cell cycle progression, cell proliferation, and
scenescence. At the molecular level, cancer of all kinds
converges in p53 pathway. Due to mutation of Rb, p53
or p16 cell cycle progresses uncontrollably and untimely.
p53 is a tumor suppressor gene and is dubbed as the
guardian of the genome. Around 50–80% tumors of various
kinds have p53 sporadic mutation [63]. The protein is
quickly degraded (half life is around 30mins). However, this
proteinisquicklyactivated(stabilized)duringviralinfection,
untimed cell cycle progression, in DNA damage, and other
stress [63]. After DNA damage the protein is phosphorylated
by ATM/ATR kinases and stabilized. The protein upregulates
the expression of the p21 gene that brakes the cell cycle
progression from G1 to S phase. Among many genes, it
also upregulates bax expression, a proapoptotic gene. During
the cell cycle blockage, p53 assesses the degree/extent of
DNA damage. If it is repairable, then it recruits/upregulates
the DNA repair proteins and restores the integrity of the
genome. But if the DNA damage is signiﬁcant, then it
directs the cells towards apoptosis. As ES and iPS cells also
proliferate rapidly, the intact p53 pathway is an impediment
of eﬃcient reprogramming. Cell cycle and apoptosis act as
a rate-limiting step during reprogramming. Anything that
accelerates cell division, helps in faster reprogramming. It
can be done if p53 is knocked down temporarily by p53
or p21 speciﬁc short hairpin (shRNA). This may facilitate
faster reprogramming but also increases the chance of
tumor development. Several labs have used temporary p53
knockdown for faster reprogramming, and then/later onStem Cells International 7
restoring p53 pathway after iPS generation helps to guard
against the development of any cancer [64].
Rem2isasuppressorofthep53pathwayandisexpressed
higherinhESC.Rem2worksbyacceleratingthecellcycleand
simultaneously protecting from apoptosis through an eﬀect
on cyclin D1. Rem 2 is a major player of hESC pluripotency
and self-renewal. Rem 2 is as eﬃcient as c-Myc and both
enhance reprogramming eﬃciency by eightfold from human
somatic cells to iPS.
8. The Epigenetical Modiﬁcation
The Epigenetical modiﬁcation has been widely observed
in cancer, during embryogenesis and cellular reprogram-
ming. During the mammalian development genomewide
epigenetic reprogramming takes place in vivo but in vitro
epigenetic reprogramming is not so eﬃcient. That is why
it takes a long time to reprogram. Epigenetic changes that
modify DNA and DNA packaging protein (called histones)
alters gene expression patterns and regulate cell identity
[65]. To reprogram the cells to iPS we need to understand
the cellular reprogramming process as well as epigenetic
changesofthegenomethatfollowsthereprogrammingsteps.
Epigenetics is deﬁned as heritable changes in phenotype or
gene expression caused by mechanisms other than changes
in the underlying DNA sequence. The epigenetic mechanism
to be considered as another dimension/language other than
DNA. Reprogramming is regulated not only by 4RFs but
also by epigenetic modiﬁcation. Epigenetic modiﬁcation
can happen at the DNA level by DNA methylation of
promoter and methylation/acetylation of proteins (histone)
that wrap the DNA; gene may be expressed or silenced. The
protein acetylation facilitates the RNA synthesis machinery
to access the promoter. Tumor suppressor gene silencing
has been reported in various cancers by epigenetic mech-
anism resulting in unrestricted cell growth. In case of
SCNT aberrant DNA methylation (epigenetic) pattern has
resulted in an inability to reach its pluripotent state during
development into blastocyst in cattle [66]. In such cases,
histone deacetylase inhibitor trichostatin A (TSA) treatment
increases the eﬃciency of development to term of SCNT
embryos [67]. The promoters of Oct3/4 and nanog are
highly methylated and silent in starting ﬁbroblast cells but
demethylated and active in iPS cells. iPS eﬃciency can be
increased by the treatment with epigenetic modiﬁcation
drugs. These may be DNA methyltransferase inhibitors like
5 -Azacytidine and RG108, histone deacetylase inhibitors
such as valproic acid and TSA, and histone methyltransferase
inhibitor BIX-01294. It was expected that iPS cells may have
the same epigenetic modiﬁcation as ES cells. Later it was
identiﬁed that there are 71 diﬀerential methylation regions
(DMRs) between ES cells and iPS cells [68]. iPS cells are
not as equal as ES cells in some aspects and iPS cells have
some memory about the tissue of origin. This was evidenced
by comperative gene expression proﬁling of ES and iPS
cells. Kang H and Roh S showed that although murine
S C N Te m b r y o sa c t i v a t e dt or e p r o g r a mw i t ho rw i t h o u tT S A
(a strong inhibitor of histone deacetylase), TSA (treated
11h) showed higher blastocyst rate (21.1%) compared to
nontreated embryos (3.4%). TSA-treated embryo showed
decreased expression of histone deacetylase (both HDAC1
and HDAC2) and DNA methylation genes (DNMT3a and
DNMT3b) where expression levels increased for expression
of histone acetyltransferase (P300 and CBP) and pluripo-
tency markers (OCT4 and NANOG). Thus chemicals like
TSA can be used to compensate for the shortcomings of iPS
[55]. Epigenetic changes happen when diﬀerentiation takes
place from pluripotency and vice versa [69]. The iPS cells
that fulﬁll pluripotent criteria may contain heterogeneous
proﬁles that aﬀect lineage-speciﬁc diﬀerentiation. Moreover,
cells reprogrammed by iPS may contain a residual memory
persistent from the original parental source as well as
some remnants of the programming process itself which
leads to biased potential to diﬀerentiate into tissues like
cardiac tissues [70]. By enforced expression of TFs, it has
shown that although distinct iPS colonies morphologically
looks like ES cells, at the molecular level they are very
heterogenous in expressing various stage-speciﬁc in diﬀer-
entiation potential. They found only one type of cells that
represents true iPS cells and others are reprogramming
intermediates. Expression of cellular markers like TRA-1-60,
DNMT3B, and REX1 can be found in fully reprogrammed
cells. Contrary to our understanding AP, SSEA-4, GDF3,
hTERT, and NANOG are insuﬃcient markers. Pluripotency
is maintained by an open chromatic state of cells. It may
be achieved in 2 ways (a) factors that keep chromatin open
globally to facilitate the entry of transcription machineries
to the gene promoters, and (b) factors that act locally
to silence the lineage speciﬁc genes until the initiation of
diﬀerentiation [71]. Bioengineered stem cells can be used for
replacement tissue for a number of diseases and has shown
therapeutic beneﬁts upon transplantation in animal models
[72]. Tursun et al. was able to convert various neuron types
(glutamatergic, cholinergic, and GABAergic) by the ectopic
expression of only one transcription factor in C.elegans. This
was achieved by the removal of the histone chaperone LIN-
53(homologoustohumanRbAp46/48)thatworksashistone
remodeling and modifying complex. It can be mimicked by
chemical inhibition of histone deacetylases [73].
9.MolecularMechanismofReprogramming
The detailed molecular mechanism of cellular reprogram-
ming is not known yet. Several of the reprogramming factors
work with protein-protein interaction. These genes bind
with promoters of several genes. Epigenetic modiﬁcation
facilitates enzymes/proteins access to the promoter. There
are 2 sets of genes with opposing functions: upregulation
of genes that are involved in stemness like STAT3 and
ZIC3 [74] and downregulation of genes that are responsible
for diﬀerentiation like PAX6, ATBF1, and SUZ12 [75].
During reprogramming of MEF, induction of SSEA-1 and
repression of Thy-1 gene are noticed at the early stage of
reprogramming [76]. More late stage endogenous pluripo-
tent markers OCT3/4 and SOX2 as well as telomerase are
expressed that add telomere at the end of chromosomes.8 Stem Cells International
Fully reprogrammed cells are positive for pluripotent marker
SSEA-4 and negative for TRA-1-60 and ﬁbroblast marker,
CD13. They are also supposed to have inactivated retroviral
promoter. iPS has been produced from various source
of adult cells like mouse liver [77], pancreatic beta cells
[78]. Work on signaling pathway shows that modulation
of Wnt/β-catenin, MAPK/ERK, TGF-β, and PI3K/AKT
signaling pathway increases the likelihood of somatic cell
reprogramming [79].
PrigioneandAdjaye2010havedemonstratedthathuman
ES and iPS both in the undiﬀerentiated state and all stages of
diﬀerentiation have similar mitochondrial properties which
aredistinctfromthoseofﬁbroblasts.Thiswasdonebyglobal
transcriptional proﬁling and suggests that mitochondrial
proﬁle remains similar upon diﬀerentiation [80].
10.Incomplete Programming
Incomplete programming of mouse colony tends to express
lineage-speciﬁc genes. CD13 markers are lost in the early
stages of iPS followed by diminished expression of GFP
and increased expression of SSEA4 and TRA-1-60. Hoechst
stainingisalsodiminishedatthelatestageofreprogramming
as stem cells tend to pump out this nuclear staining dye.
In summary, starting with CD13+ human ﬁbroblasts, at the
1st and 2nd stages of dediﬀerentiation, both have GFP+,
Hoechst bright and TRA-1-60 negative. But at the 2nd stage
SSEA-4 positive which is negative in the 1st stage. Stages
2 and 3, both have CD13-, SSEA4+; GFP is negative at
stage 3 but positive at stage 2; TRA-1-60 is positive at
stage 3 and negative at stage 2; Hoechst is dim in stage
3 but bright at stage 2. However, the above-mentioned
markers are not always enough as cells expressing these
markers sometimes fail to expand. Together with these
markers and growth properties they help to identify the
real iPS cell lines. T h ei n c o m p l e t e l yr e p r o g r a m m e dc e l l sm a y
self-renew due to the presence of c-Myc. Removal of c-Myc
from reprogramming factors has shown signiﬁcantly decreased
number of incompletely reprogrammed colonies in the mouse
and human [10]. For that reason, Hanna et al. used a soluble
wnt3a that promotes iPS regeneration in the absence of c-Myc.
Wnt-3aconditionedmediacanreprogramMEFcells [36].Wnt
signalling results in inhibition of GSK-3 and stabilization of
cytoplasmic β-catenin.
Li et al. has created iPSC from somatic cell by genetic
transduction that remains homogeneous. They developed a
method where both human and rat iPSCs (riPSCs) can be
maintained by LIF and a cocktail of ALK5 inhibitor, GSK3
inhibitor, and MEK inhibitor [60].
11.Determinationof CellIntegrityafteriPS
Before using iPS for lineage-speciﬁc diﬀerentiation, the
qualityandgeneticintegrityofiPScellsaredetermined.Cells
are karyotyped to rule out any chromosomal aberrations
and cells should be conﬁrmed as diploid, normal. Expression
of exogenous pluripotency markers and nonintegration of
LGNSOgenestohostchromosomeisdeterminedbyRT-PCR
and standard Southern blotting, respectively. To examine the
coexpression of Lin28, Nanog, Sox2, and Oct4, transfected
cells are subjected to Western blot or immunoﬂuorescence
analysis. Pluripotency is determined in vitro and in vivo.
EB formation is one of the hallmarks for in vitro diﬀer-
entiation of ES cells. Teratoma formation in vivo is a test
for pluripotency. Spontaneous diﬀerentiation of MC-iPS
cells into mesoderm, endoderm, and ectoderm lineages is
detected by immunoﬂuorescence and RT-PCR of genes that
are speciﬁc for diﬀerentiation. To examine the in vivo devel-
opmental potential of human iPS cells generated through
reprogramming, cells are injected into the dorsal ﬂank of
6-week-old immune-compromised SCID-beige mice. After
eight weeks, teratoma formation is evaluated.
12. Conclusion
Although iPS cells are easy to create in the lab ES cells are the
gold standards. The ES cells are far more eﬃcient in deriving
other types of tissues than iPS. However, using ES cells is not
easy due to ethical reasons. Since the establishment of iPS
as an alternative to ESC, a new avenue has opened in stem
cell research. Now cells can be autologously reprogramed
to pluripotency for therapeutic applications. Any adult cells
like skin cells, muscle cells, and adipose tissue cells have
been used for reprogramming purposes. The original viral
transduction method has evolved to reprogramming meth-
ods where reprogramming factors can be delivered without
viral vectors thus genome remained unperturbed. This has
been done by plasmid, protein, mRNA transfection, and
minicircle nucleofection. Diﬀerent cell types have diﬀerent
levels of reprogramming potency and diﬀerent level of
requirements of reprogramming factors. This may suggest
that there is still undiscovered factors remained that are
needed for eﬃcient and quick generation of iPS. On the
other hand, some cells express few factors abundantly than
other kind of cells thus obviating the necessity of the
reprogramming factor for that cell type. Teratoma formation
from iPS is a drawback and needs careful screening of iPS
that gives rise to teratoma in vivo. Direct reprogramming
(iPS) is in nascent stage. Further research will facilitate the
possibility of iPS in wide ranging of tissue engineering and
regenerative medicine making the technology more available
for therapeutic purposes.
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